Ingrid Mayer

October 28, 2021

VICC’s Mayer departing to take new role with AstraZeneca

Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

By Tom Wilemon
May 26, 2021

Vanderbilt researchers present new data on clinical trials at ASCO 2021

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

By Tom Wilemon
April 23, 2020

Health workers sought for hydroxychloroquine study

Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

By Bill Snyder
August 22, 2019

Grant strengthens breast cancer research efforts

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

By Tom Wilemon
July 8, 2019

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

By Leigh MacMillan
April 19, 2018

VUMC drug repurposing initiative gaining momentum

Drug repurposing involves establishing an additional approved indication for a drug already at market.

By Paul Govern
April 12, 2018

VICC breast cancer leaders named Komen Scholars

Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a Komen Scholar for her leadership in breast cancer research.
By VUMC News and Communications
October 26, 2017

Study to test combination therapy for breast cancer

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
By VUMC News and Communications
March 23, 2017

Breast cancer program lands new research grants

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.
By VUMC News and Communications
May 26, 2016

Precision medicine already changing cancer treatment strategies

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.
By VUMC News and Communications